WHO ICTRP trial
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With…
CTRI/2010/091/001238 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2010/091/001238 |
|---|---|
| Public title | A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. |
| Scientific title | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus. |
| Primary sponsor | GlaxoSmithKline |
| Secondary sponsors | PPD Pharmaceutical Development India Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India;Australia;Brazil;Colombia;Germany;Peru;Philippines;Republic of Korea;Russian Federation;South Africa;Spain;Taiwan;United Kingdom;United States of America |
| Conditions | Health Condition 1: null- Diabetes Mellitus, Type 2 |
| Interventions | Intervention1: Albiglutide: Experimental: weekly subcutaneous injection Control Intervention1: Liraglutide: Active Comparator: liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance… |
| Registration date | Sep 29, 2010 |
| Target size | 800 |
| Secondary IDs | GLP114179 dated 22 Mar 2010;NCT01128894 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: